Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D9TY | ISIN: US74365N2027 | Ticker-Symbol: MBP
München
17.04.24
08:04 Uhr
1,280 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PROTAGENIC THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTAGENIC THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2501,34017.04.

Aktuelle News zur PROTAGENIC THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiProtagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit288Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical...
► Artikel lesen
01.04.Protagenic Therapeutics GAAP EPS of -$1.151
01.04.Protagenic Therapeutics, Inc.: Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results196Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized...
► Artikel lesen
01.04.Protagenic Therapeutics, Inc.\new - 10-K, Annual Report2
27.03.Protagenic Therapeutics, Inc.: Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders163Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission...
► Artikel lesen
25.03.Protagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call252Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company...
► Artikel lesen
21.03.Protagenic Therapeutics, Inc.\new - 8-K, Current Report1
21.03.Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice210NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price...
► Artikel lesen
13.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 44.301The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS42328V8019 HELIUS...
► Artikel lesen
13.02.Protagenic advances in stress disorder treatment trial1
13.02.Protagenic Therapeutics, Inc.: Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders430Company Anticipates Reporting Complete Phase I Single Dose Results in AprilNEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator...
► Artikel lesen
15.12.23Protagenic Therapeutics, Inc.\new - 8-K, Current Report3
12.12.23Protagenic Therapeutics, Inc.: Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals580Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis...
► Artikel lesen
29.11.23Protagenic Therapeutics, Inc.\new - 8-K, Current Report2
14.11.23Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report1
13.10.23Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Date of Annual Shareholder Meeting876NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...
► Artikel lesen
26.09.23Protagenic Therapeutics, Inc.: Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114763A potential major step toward treating stress-related neuro-psychiatric disordersNEW YORK, NY / ACCESSWIRE / September 26, 2023 / Today, Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneering biopharmaceutical...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1